Biocon Ltd. — Capital/Financing Update 2025

Jan 31, 2025

==> picture [132 x 53] intentionally omitted <==

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T: 91 80 2808 2808 F: 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/SP/2024-25/170

January 31, 2025

To,The SecretaryBSE LimitedDepartment of Corporate ServicesPhiroze Jeejeebhoy Towers,Dalal Street,Mumbai – 400 001	To,The SecretaryNational Stock Exchange of India LimitedCorporate Communication DepartmentExchange Plaza, Bandra Kurla ComplexMumbai – 400 050
Scrip Code – 532523	Scrip Symbol - Biocon

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

In reference to our letter dated January 30, 2025, regarding the approval of the Board of Directors at its meeting held on January 30, 2025, for purchase of 1,97,99,305 equity shares of Biocon Biologics Limited (BBL), material subsidiary of the Company, we further wish to inform you that the said transaction of acquisition/ purchase has been completed today.

Further, the details as required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed herewith as Annexure I .

The above-mentioned information will also be available on the website of the Company at www.biocon.com.

Kindly take the above information on record and acknowledge.

Thanking You,

For Biocon Limited

MAYANK Digitally signed by MAYANK VERMA VERMA Date: 2025.01.31 19:20:41 +05'30' _______________ Mayank Verma Company Secretary and Compliance Officer Membership No.: ACS 18776

Encl: as above

==> picture [132 x 53] intentionally omitted <==

Annexure I

Sl. No.	Particulars	Particulars	Particulars	Details	Details	Details	Details
1	Name of the target entity, details in brief such			Biocon Biologics Limited (BBL), material
	as size, turnover etc.			subsidiary of Biocon Limited, incorporated
				under t	e Companies Act, 2013, and having
				corporaU2411	teidentificatioKA2016FLC093936	nnumberdi
				reister	,d office at Biocon	antsHose Grond
				gFloor	ower-3 Semicon P	u, uark Electronic
				,City P	,hase-II Hosur Ro	,d Bengaluru-
				,560100	,	,
				Net wo	rth of BBL as on 3	1.03.2024: INR
				176,062	.65 Mn.
				Turnove	r of BBL as on 3	1.03.2024: INR
				30,932.	50 Mn.
2	Whether the a	cquisition would f	all within	Purchas	e of 1,97,99,305 e	quity shares of
	related party tr	ansaction(s) and wh	ether the	BBL fro	m one of its exi	sting investors
	promoter/ prom	oter group/ group c	ompanies	pursuan	t to liquidity optio	n exercised by
	have any interes	t in the entity being	acquired?	them i	n terms of existing	shareholder’s
	If yes, nature of i	nterest and details t	ereof and	agreem	ent.
	whether the sam	e is done at “arm’s	length”
3	Industry to whi	ch the entity being	acquired	Pharma	ceuticals.
	belongs
4	Objects and im	pact of acquisition	(including	Purchas	e of 1,97,99,305 e	quity shares of
	but not limitedf	to, disclosure of rf	asons for	BBL fr	m one of its exil	sting investors
	acquisition o tid h i	arget entity, i itsn line of business of	usiness isthe listed	pursuathem.	t to iquidity optio	n exercised by
	outse te ma
	entity)
		ny governmental or	regulatory	Not App	licable.
5	Brief details of a
	approvals requir	ed for the acquisitio	n
6	Indicative time	period for completi	on of the	The pur	chase of shares has b	een completed
	acquisition			todayi.	e. January31,2025.
		whether cash considth f d d	eration oril f th	Cash co	nsideration.
7	Consideration -h
	sare swap or asame	y oer orm an e	as o e
8	Cost of acuisit	on and/or the ric	at which	Rs 555	0 Mn
	qthe shares are a	pcquired		. ,	.
9	Percentage of s	hareholding / contro	l acquired	1.5% of	the equity share cap	ital of BBL.
	and / or number	of shares acquired
				Post thiBBL is 9	s purchase, Biocon Li0.2%.	mited's stake in
10	Brief backgroun	d about the entity a	cquired in	BBL wa	s incorporated in In	dia on June 8,
	terms of produ	cts/line of businessration, history of la	acquired,st 3 years	2016, wbiosimil	ith an objective to sear biologics facilities	t up Greenfield.
	date of incorpo
	turnover, count	ry in which the acquand any other	red entitysignificant	Biocon	Biologics Limited (B	BL), a material
	has presence
	information (in	rief)		subsidiafull int	ry of Biocon Limiterated lobal biosi	d, is a unique,ilars coman
				ycommit	g, gted to transforming	pyhealthcare and
				transforming lives. It is capitalizing on its‘lab to market’ capabilities to serve millionsofpatients across 120+ countries by

==> picture [132 x 53] intentionally omitted <==

enabling affordable access to high quality
biosimilars. BBL is leveraging cutting-edge
science, innovative tech platforms, global
scale manufacturing capabilities and world-
class quality systems to lower costs of
biological therapeutics while improving
healthcare outcomes. It has commercialized
eight biosimilars in key emerging markets
and advanced markets like U.S., Europe,
Australia, Canada, and Japan. It has a
pipeline of 20 biosimilar assets across
diabetology,oncology,immunology,
ophthalmology,andothernon-
communicable diseases. It has many ‘firsts’
to its credit in the biosimilars industry. As
part of its environmental, social and
governance (ESG) commitment, it is
advancing the health of patients, people,
and the planet to achieve key UN
Sustainable Development Goals (SDGs).
Last 3 years turnover (in INR Mn):
FY22: INR 23,625.15 Mn.
FY23: INR 20,923.83 Mn.
FY24: INR 30,932.50 Mn.